Dr. Helen Han Hsu joined Biosion’s team as a non-clinical and pathology expert consultant who has over 30 years of experience in the pharmaceutical industry, including 20+ years in the US, and 13 years in China.  Dr. Hsu’s consulting business has provided expertise in registration strategy, non-clinical development program building, interaction with China NMPA, and evaluation/peer review of toxicological pathology studies. Helen was Vice President of PreClinical Development, Asia Pacific, Janssen Pharmaceuticals for 12 years, based in Shanghai, responsible for supporting Janssen China R&D early and late drug development including global drug registration.  She served on global and China senior leadership teams and contributed to organizational building. Dr. Hsu was an active member of RDPAC, through which helped shaped China CDE’s evolution, and finally adherence to ICH guidelines.  She was recognized by RDPAC with an outstanding contribution award in 2019. Before transferring to China, Helen was Sr. Director of Toxicology, Pathology and Laboratory Animal Medicine, ensuring the scientific and operational quality of US early development programs. Before joining Janssen, she worked with Novartis Pharmaceuticals and Wyeth Laboratory, where she advanced from bench pathologist to Director of Pathology. 

Dr. Hsu is a Diplomate of American College of Veterinary Pathologists. She earned a Ph.D. from Department of Veterinary Medicine, Cornell University and completed a pathology residency in the same department. She has a DVM degree from National Taiwan University.